At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 49 enrolled
Drug / intervention
androgel +2 moredrug
Likely dose
androgel 10gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Androgel on Inflammatory Mediators and Oxidative Stress in Type 2 Diabetic Males With Hypogonadism
In Brief
A Phase 4 clinical trial evaluating androgel, androgel 10g, and 1 other intervention for Diabetes Mellitus Type 2. Completed, enrolled 49 participants across 1 site.
Detailed Summary
This is to study the effect of replacing testosterone on different inflammatory cells in type 2 diabetics with low testosterone levels.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus Type 2
CountriesUnited States
CollaboratorsSolvay Pharmaceuticals
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2006
First PostedJul 2006
Primary CompletionJun 2013
Study CompletionJul 2013
TodayJul 2026
First PostedJul 11, 2006
Enrollment StartJul 1, 2006
Primary CompletionJun 1, 2013
Study CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 20.0 years ago
Interventions
androgeldrug
androgel 5g
androgel 10gdrug
androgel 10g
placebodrug
placebo